and we may have identified DLL3 as the first predictive biomarker in this disease," Dr. Charles Rudin, an oncologist at Memorial Sloan Kettering who led the study, said in a release. Rudin said ...
according to Charles Rudin of Memorial Sloan Kettering Cancer Center in New York, who presented the data at WCLC. On safety, there was a case of interstitial lung disease (ILD), a side effect that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback